Fig. 1 · Structure

Documents & Downloads

Arctiin

Cat. No. A12019 CAS 20362-31-6
Arctiin has shown to be a suppressor of cyclin D1 protein expression in multiple types of human tumor cells, such as osteosarcoma, lung, colorectal, cervical, breast, melanoma, and prostate cancer

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
MRC5 IC50 16 μM Antiviral activity against HCMV in MRC5 cells by plaque reduction assay [PMID: 17239594]
RAW264.7 IC50 > 0.3 mM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs [PMID: 18986199]

Arctiin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Arctiin from 3 published references. In vitro models include MDA-MB-231 cells; RAW264.7 cells.

Arctiin In Vitro Studies

Arctiin treatment for 72 hours yielded a cell viability IC50 of 3.2±0.3 µM in MDA-MB-231 cells. In MCF-7 cells, the cell viability IC50 was >10 µM after 72 hours. In RAW264.7 cells, Arctiin did not affect normal cell growth at concentrations up to 100 μg/ml. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Arctiin and viability in breast cancer cells

Cell-based study · MDA-MB-231 cells [1]

MDA-MB-231 cells were treated with Arctiin for 72 hours, with vehicle controls. The cell viability IC50 was 3.2±0.3 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityIC50 3.2±0.3 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM to 1.2 nM
Exposure duration
72 hours
Method
culture media containing either vehicles or drug were added
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Arctiin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Proliferation Assays (S55, S56, S58); Results > Hit Compounds Inhibit the Growth of AdipoR1/AdipoR2– Positive Cancer Cell Lines (S116); Table 3 (T3.h1, T3.h2, T3.r1)

cell viability: cell viability; comparator: vehicle controls — Results > Hit Compounds Inhibit the Growth of AdipoR1/AdipoR2– Positive Cancer Cell Lines (S116); Table 3 (T3.h1, T3.h2, T3.r1)

Arctiin and normal cell growth

Cell-based study · RAW264.7 cells [2]

RAW264.7 cells were treated with Arctiin at concentrations up to 100 μg/ml. Arctiin did not affect normal cell growth at these concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viabilityReported result arctiin did not affect normal cell growth at concentrations up to 100 μg/ml[2]

Literature-Reported Treatment Conditions

Treatment concentration
up to 100 μg/ml
Method
plated with various concentrations of arctiin
Reported limits
Not stated in the sentences used: schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Arctiin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cell viability assay (S18, S19); Results (S51); Figure 1 legend (S77)

Cell viability: Cell viability — Results (S51); Figure 1 legend (S77)

Arctiin and viability in mammary cells

Cell-based study · MCF-7 cells [1]

MCF-7 cells were treated with Arctiin for 72 hours, with vehicle controls. The cell viability IC50 was >10 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityIC50 >10 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM to 1.2 nM
Exposure duration
72 hours
Method
culture media containing either vehicles or drug were added
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Arctiin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Proliferation Assays (S55, S56, S58); Results > Hit Compounds Inhibit the Growth of AdipoR1/AdipoR2– Positive Cancer Cell Lines (S116); Table 3 (T3.h1, T3.h2, T3.r1)

cell viability: cell viability; comparator: vehicle controls — Results > Hit Compounds Inhibit the Growth of AdipoR1/AdipoR2– Positive Cancer Cell Lines (S116); Table 3 (T3.h1, T3.h2, T3.r1)

Arctiin In Vivo Studies

Arctiin was administered by intraperitoneal injection at 10 mg/kg to male mice with DMM-induced articular cartilage abrasion. The comparison isolating the compound effect showed a 50.8% decrease in OARSI score relative to DMM controls. [3]

Arctiin and cartilage abrasion in mice

Animal study · DMM-induced articular cartilage abrasion in seven-week-old C57BL/6J male mice [3]

Male mice with DMM-induced articular cartilage abrasion received Arctiin by intraperitoneal injection at 10 mg/kg. The comparison isolating the compound effect showed a 50.8% decrease in OARSI score relative to DMM controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Osteoarthritis Research Society International (OARSI) score (n = 6)OARSI score 50.8% decrease in OARSI score[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
One week after surgery; twice a week; Eight weeks after DMM surgery
Vehicle
DMSO; 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Arctiin 10 mg/kg; 10 mg/mLDMM50.8% decrease in OARSI score[3]
Arctiin 10 mg/kg; 10 mg/mL
Model: DMM-induced articular cartilage abrasion in seven-week-old C57BL/6J male mice
Methods and source locations

Compound reported in the paper: Arctiin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > DMM-induced mice OA (S64, S67); Materials and methods > Animal treatment (S68, S69, S70, S71); Materials and methods > Histology and immunohistochemistry (IHC) (S82); Results > Systemic administration of arctiin ameliorates cartilage degeneration (S122, S123, S125, S126, S131)

Osteoarthritis Research Society International (OARSI) score (n = 6): Osteoarthritis Research Society International (OARSI) score (n = 6); comparator: DMM — Results > Systemic administration of arctiin ameliorates cartilage degeneration (S125, S131)

Arctiin 10 mg/kg; 10 mg/mL · Materials and methods > Animal treatment (S69, S71); Results > Systemic administration of arctiin ameliorates cartilage degeneration (S122, S123, S125)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 20362-31-6
Formula C27H34O11
Molecular Weight 534.55
Synonyms Arctigenin-4-glucoside
SMILES
COC1=C(C=C(C=C1)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (179.59 mM)
Water 38 mg/mL (71.08 mM)
Ethanol 96 mg/mL (179.59 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Arctiin Research References

  1. [1] Sun Y, Zang Z, Zhong L, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One (2013). PMID: 23691032 DOI: 10.1371/journal.pone.0063354 Source material
  2. [2] Lee S, Shin S, Kim H, et al. Anti-inflammatory function of arctiin by inhibiting COX-2 expression via NF-κB pathways. J Inflamm (Lond) (2011). PMID: 21733191 DOI: 10.1186/1476-9255-8-16 Source material
  3. [3] Liu Y, Hou M, Pan Z, et al. Arctiin-reinforced antioxidant microcarrier antagonizes osteoarthritis progression. J Nanobiotechnology (2022). PMID: 35761235 DOI: 10.1186/s12951-022-01505-7 Source material

Added to your cart

View Cart Checkout
Loading...